Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio

Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a staggering $4.3 billion, a move that ... Read More